

Webcast: Life Sciences 2024 Outlook

Webcasts | March 12, 2024

The past five years have been particularly tumultuous in the biopharma sector. Strong capital markets and M&A activity into early 2020 were whipsawed during the pandemic, with equity valuations climbing significantly through early 2021 before dropping dramatically through the fourth quarter of 2023. Join our team of seasoned attorneys and industry leaders where we provide a recap of 2023 highlights for capital markets, M&A activity, royalty finance transactions and clinical funding arrangements, along with expectations for the Life Sciences deal market in 2024.

Related People

[Branden C. Berns](#)

[Melanie E. Neary](#)

PANELISTS: **Branden Berns** is a partner in the San Francisco office of Gibson, Dunn & Crutcher, where he practices in the firm's Corporate Transactions Practice Group, focusing on representing leading life sciences companies and investors. Branden advises clients in connection with a variety of financing transactions, including initial public offerings, secondary equity offerings and venture and growth equity financings, as well as complex corporate transactions, including mergers and acquisitions, asset sales, spin-offs, joint ventures, PIPEs and leveraged buyouts. Mr. Berns regularly serves as principal outside counsel for publicly-traded companies and advises management and boards of directors on corporate law matters, SEC reporting and corporate governance. **Melanie Neary** is a senior associate in the San Francisco office of Gibson, Dunn & Crutcher, where she practices in the firm's Corporate Transactions Practice Group, with a practice focused on advising clients in connection with a variety of financing transactions, including initial public offerings, secondary equity offerings and venture and growth equity financings as well as complex corporate transactions, including mergers and acquisitions. Melanie also regularly advises clients on corporate law matters, Securities and Exchange Commission reporting requirements and ownership filings and corporate governance. **Yasha Dyatlovitsky** is a Managing Director in TD Cowen's Private Capital Solutions Group focused exclusively on healthcare. Mr. Dyatlovitsky has over 20 years of experience in leveraged finance and structured credit products. Since 2020, he has helped companies raise over \$7B in financing across debt, royalty, and preferred equity transactions. Mr. Dyatlovitsky joined TD Cowen in 2018 from Stifel, where he served as a Director in its Debt Capital Markets group. Mr. Dyatlovitsky started his career in the securitization group at Lehman Brothers, where he traded and securitized adjustable rate mortgage products.

MCLE CREDIT INFORMATION: This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 1.0 credit hour, of which 1.0 credit hour may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit. Attorneys seeking New York credit must obtain an Affirmation Form prior to watching the archived version of this webcast. Please contact CLE@gibsondunn.com to request the MCLE form. Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 1.0 hour. California attorneys may claim "self-study" credit for viewing the archived version of this webcast. No certificate of attendance is required for California "self-study" credit © 2024 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and

GIBSON DUNN

circumstances may vary, and prior results do not guarantee a similar outcome.

Related Capabilities

[Life Sciences](#)